Partnering with Bayer
We partner with the best and the brightest to prevent, treat and reverse diseases and change lives of patients through digital and health technologies.
"We believe the most meaningful innovations emerge when strong partners bring together complementary science, capabilities, and ambition."
Bayer is committed to external innovation
With over 160 years of experience and a presence in 83 countries, Bayer offers a deep understanding of global markets and diverse regulatory landscapes, establishing a reputation as a science-driven and data-focused partner.
What is Bayer's Partnership Strategy?
Bayer’s partnering strategy is driven by a commitment to developing groundbreaking treatments that transform healthcare and create a better future for patients worldwide.
Bayer is built to partner early, flexibly, and for the long term. Our collaboration model is designed to meet innovators where they are, with open communication, adaptable deal structures, and support that extends well beyond signing.
We are modality-agnostic and science-led, pursuing high-potential innovation across cell and gene therapies, AI and data analytics, digital health, and other emerging technologies from discovery through commercialization.
Bayer fuels innovation through diverse partnership models, from licensing and acquisitions to joint ventures and localized collaborations. We prioritize nurturing scientific innovation through adaptable deal structures and ongoing support, even after deal closure, going beyond the limitations of traditional licensing agreements.
Collaborate with us!
Working together fuels innovation, and true visionaries permeate the life sciences. Opportunities are right in front of us, spearheaded by groups and companies like yours. If you want a partner who will help you reach the next level, we’re here for you.